{{Rsnum
|rsid=6449174
|Gene=SLC2A9
|Chromosome=4
|position=9964798
|Orientation=plus
|GMAF=0.3912
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC2A9
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 34.5 | 46.0 | 19.5
| HCB | 81.0 | 19.0 | 0.0
| JPT | 85.8 | 14.2 | 0.0
| YRI | 7.5 | 46.6 | 45.9
| ASW | 8.8 | 59.6 | 31.6
| CHB | 81.0 | 19.0 | 0.0
| CHD | 73.4 | 22.9 | 3.7
| GIH | 59.4 | 35.6 | 5.0
| LWK | 16.7 | 40.7 | 42.6
| MEX | 31.0 | 50.0 | 19.0
| MKK | 19.4 | 50.3 | 30.3
| TSI | 37.3 | 48.0 | 14.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6449174
|Name_s=
|Gene_s=SLC2A9
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109485
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6449174
|overall_frequency_n=52
|overall_frequency_d=128
|overall_frequency=0.40625
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=50
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}